Antiarrhythmic drug therapy of ventricular arrhythmias.
D000638:Amiodarone / Q000627:therapeutic use; D000889:Anti-Arrhythmia Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001145:Arrhythmias, Cardiac / Q000188:drug therapy*; D001950:Bretylium Tosylate / Q000627:therapeutic use; D004206:Disopyramide / Q000627:therapeutic use; D005424:Flecainide; D006352:Heart Ventricles / Q000187:drug effects; D006801:Humans; D008012:Lidocaine / Q000031:analogs & derivatives / Q000627:therapeutic use; D008801:Mexiletine / Q000627:therapeutic use; D016293:Moricizine; D010640:Phenothiazines / Q000627:therapeutic use; D010672:Phenytoin / Q000627:therapeutic use; D010880:Piperidines / Q000627:therapeutic use; D011342:Procainamide / Q000627:therapeutic use; D011405:Propafenone; D011427:Propiophenones / Q000627:therapeutic use; D011802:Quinidine / Q000627:therapeutic use; D013015:Sotalol / Q000627:therapeutic use; D016677:Tocainide; D014700:Verapamil / Q000627:therapeutic use
D000889:Anti-Arrhythmia Agents; D010640:Phenothiazines; D010880:Piperidines; D011427:Propiophenones; D008801:Mexiletine; D016677:Tocainide; D016293:Moricizine; D010672:Phenytoin; D011405:Propafenone; D001950:Bretylium Tosylate; D008012:Lidocaine; D013015:Sotalol; D014700:Verapamil; D004206:Disopyramide; D011802:Quinidine; D005424:Flecainide; D011342:Procainamide; D000638:Amiodarone